Prima BioMed announced what it called positive trends in the interim data from the CAN-003 phase 2 clinical trial of CVac to treat epithelial ovarian cancer patients in remission after first-line or second line therapy. Interim progression free survival data show a favourable trend toward patients receiving CVac staying in remission longer than those in the observational standard of care group, the company said. Combining overall data of first and second remission, the median progression free survival time is 421 days for non-randomized CVac, 365 days for CVac, and 321 days for OSC. The first seven patients on the study were not randomized and all seven were assigned to receive CVac in accordance with the trial design. Safety data to date indicate that CVac is very well tolerated as compared to observational standard of care, the company added.